MX2011000767A - Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. - Google Patents

Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Info

Publication number
MX2011000767A
MX2011000767A MX2011000767A MX2011000767A MX2011000767A MX 2011000767 A MX2011000767 A MX 2011000767A MX 2011000767 A MX2011000767 A MX 2011000767A MX 2011000767 A MX2011000767 A MX 2011000767A MX 2011000767 A MX2011000767 A MX 2011000767A
Authority
MX
Mexico
Prior art keywords
influenza
antibodies
relates
neutralizing anti
virus antibodies
Prior art date
Application number
MX2011000767A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of MX2011000767A publication Critical patent/MX2011000767A/es

Links

Classifications

    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011000767A 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. MX2011000767A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8383808P 2008-07-25 2008-07-25
US18158209P 2009-05-27 2009-05-27
PCT/IB2009/006616 WO2010010466A2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2011000767A true MX2011000767A (es) 2011-09-21

Family

ID=41570664

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011000767A MX2011000767A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX2011000768A MX2011000768A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000768A MX2011000768A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Country Status (20)

Country Link
US (2) US8685402B2 (Direct)
EP (2) EP2313433A2 (Direct)
JP (3) JP5607620B2 (Direct)
KR (2) KR101732056B1 (Direct)
CN (2) CN102216327A (Direct)
AU (2) AU2009275226B2 (Direct)
BR (1) BRPI0911699B8 (Direct)
CA (2) CA2731686C (Direct)
CO (1) CO6341572A2 (Direct)
CR (2) CR20110079A (Direct)
EC (1) ECSP11010823A (Direct)
ES (1) ES2662519T3 (Direct)
GT (1) GT201100023A (Direct)
IL (2) IL210771A0 (Direct)
MA (1) MA32577B1 (Direct)
MX (2) MX2011000767A (Direct)
NZ (2) NZ590891A (Direct)
RU (1) RU2553325C2 (Direct)
WO (2) WO2010010466A2 (Direct)
ZA (2) ZA201101113B (Direct)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970483A (zh) 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2313433A2 (en) * 2008-07-25 2011-04-27 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US9573991B2 (en) * 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US20140031418A1 (en) * 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
BR112014000263B1 (pt) * 2011-07-14 2022-01-18 Janssen Vaccines & Prevention B.V. Anticorpo isolado capaz de se ligar especificamente à proteína hemaglutinina (ha) dos subtipos de vírus influenza b, e, composição farmacêutica que o compreende
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
LT3418300T (lt) * 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
EP2739312B1 (en) * 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
WO2013030165A1 (en) * 2011-08-27 2013-03-07 Universität Zürich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
US9475861B2 (en) 2011-09-30 2016-10-25 Celltrion Inc. Binding molecule having influenza A virus-neutralizing activity produced from human B cell
AU2012326025B2 (en) * 2011-10-18 2017-08-31 Emory University Antibodies directed against influenza
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
CA2892992A1 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
EP2793945B1 (en) * 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
WO2013088367A1 (en) * 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
WO2013089496A1 (ko) * 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
RU2502745C2 (ru) * 2011-12-30 2013-12-27 Общество с ограниченной ответственностью "Технофарма" Наноантитело "anti-flu", рекомбинантные вирусные векторы и фармацевтические композиции для профилактики и терапии гриппа типа а
CN108640989B (zh) * 2012-03-08 2021-12-14 扬森疫苗与预防公司 可结合并中和b型流感病毒的人类结合分子及其用途
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2846833A4 (en) * 2012-05-10 2016-01-06 Massachusetts Inst Technology MEANS FOR INFLUENZOEUTRALIZATION
CN103665156B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的结合分子3e1
CN103665155B (zh) * 2012-09-14 2016-07-06 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1f2
CN103665157B (zh) * 2012-09-14 2016-06-29 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1c4
CN103665154B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子3c4
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
HK1223301A1 (zh) 2013-03-14 2017-07-28 Contrafect Corporation 基於鼻内递送中和抗体以增强治疗效力的组合物和方法
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
EP2982691B1 (en) * 2013-04-02 2020-05-06 Xiamen University Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
JPWO2015068781A1 (ja) * 2013-11-06 2017-03-09 国立大学法人大阪大学 インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN110642944B (zh) * 2014-03-07 2021-06-11 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
SG11201609207SA (en) 2014-05-13 2016-12-29 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
WO2016010978A1 (en) * 2014-07-14 2016-01-21 The Penn State Research Foundation Compositions and methods for targeting of the surfactant protein a receptor
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016010160A1 (ja) * 2014-07-18 2016-01-21 国立感染症研究所長が代表する日本国 抗インフルエンザウイルス抗体及びその利用
US20180008702A1 (en) 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
HRP20211510T1 (hr) * 2015-06-01 2021-12-24 Medimmune, Llc Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) * 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2018030777A1 (ko) * 2016-08-10 2018-02-15 ㈜셀트리온 항-인플루엔자 바이러스 항체의 안정한 액체 약제학적 제제
JP2017086068A (ja) * 2016-10-31 2017-05-25 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
RU2656142C1 (ru) * 2016-12-30 2018-05-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA1
RU2664184C2 (ru) * 2016-12-30 2018-08-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1
RU2671477C2 (ru) * 2016-12-30 2018-10-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SMT202400080T1 (it) 2017-02-28 2024-05-14 Univ Pennsylvania Vettore di clade f di virus adenoassociato (aav) e relativi usi
KR20190135000A (ko) 2017-02-28 2019-12-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Aav 벡터를 기반으로 하는 인플루엔자 백신
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
EP3684927B1 (en) 2017-09-18 2024-05-29 Amyris, Inc. Methods for genomic integration for kluyveromyces host cells
CN111433369A (zh) * 2017-09-18 2020-07-17 阿迈瑞斯公司 用于毕赤酵母和其他宿主细胞基因组整合的方法
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
JP7317047B2 (ja) * 2018-01-23 2023-07-28 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
WO2020022272A1 (ja) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 インフルエンザワクチンを含む組成物
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
CA3132578A1 (en) 2019-03-04 2020-09-10 Japan As Represented By Director General Of National Institute Of Infectious Diseases Method for producing influenza ha split vaccine
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
BR112022011350A2 (pt) 2019-12-11 2022-08-23 Visterra Inc Composições e métodos para tratamento e prevenção da influenza
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
IL303236A (en) 2020-12-01 2023-07-01 Univ Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral dna vectors expressing therapeutic antibodies and uses thereof
JP2025509607A (ja) 2022-03-14 2025-04-11 ジェネレーション バイオ カンパニー 異種プライムブーストワクチン組成物及び使用の方法
KR20240088574A (ko) 2022-11-21 2024-06-20 (주)샤페론 인플루엔자 바이러스에 대한 단일 도메인 항체 및 이의 용도
CN119930806B (zh) * 2025-01-21 2025-12-02 中国医学科学院病原生物学研究所 一种甲型流感病毒中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630064A (en) * 1899-02-10 1899-08-01 William Martindale Safety-hook.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
RU2031941C1 (ru) * 1991-03-14 1995-03-27 Научно-исследовательский институт гриппа РАМН Штамм вируса гриппа а(нini) для получения живой гриппозной интраназальной вакцины для взрослых и детей
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP4656478B2 (ja) * 2000-02-22 2011-03-23 株式会社医学生物学研究所 抗体ライブラリー
US7175999B2 (en) 2002-07-11 2007-02-13 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CN1756562A (zh) * 2003-03-07 2006-04-05 麦克公司 流感病毒疫苗
EP1666059A4 (en) 2003-08-11 2008-08-27 Univ Osaka Res Found NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
PT2532679T (pt) * 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
US8192927B2 (en) * 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
EP2313433A2 (en) 2008-07-25 2011-04-27 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof

Also Published As

Publication number Publication date
WO2010010467A2 (en) 2010-01-28
EP2313112B1 (en) 2017-12-27
ZA201101150B (en) 2012-08-29
KR20110047193A (ko) 2011-05-06
WO2010010466A3 (en) 2010-07-29
RU2011105062A (ru) 2012-08-27
JP2011528901A (ja) 2011-12-01
GT201100023A (es) 2013-12-10
ECSP11010823A (es) 2011-08-31
JP2011528902A (ja) 2011-12-01
NZ590890A (en) 2013-05-31
US20100080813A1 (en) 2010-04-01
AU2009275227A1 (en) 2010-01-28
CO6341572A2 (es) 2011-11-21
ZA201101113B (en) 2012-08-29
BRPI0911699A2 (pt) 2014-09-23
CN102164613A (zh) 2011-08-24
US20100086555A1 (en) 2010-04-08
EP2313433A2 (en) 2011-04-27
KR101732056B1 (ko) 2017-05-02
CA2731686C (en) 2020-04-07
BRPI0911699B8 (pt) 2023-02-28
MA32577B1 (fr) 2011-08-01
HK1161110A1 (zh) 2012-08-24
WO2010010467A3 (en) 2010-12-16
KR20110049802A (ko) 2011-05-12
EP2313112A2 (en) 2011-04-27
JP6022515B2 (ja) 2016-11-09
CA2731686A1 (en) 2010-01-28
US9340603B2 (en) 2016-05-17
US8685402B2 (en) 2014-04-01
AU2009275226B2 (en) 2015-05-14
JP5607620B2 (ja) 2014-10-15
IL210771A0 (en) 2011-03-31
AU2009275226A1 (en) 2010-01-28
CN102164613B (zh) 2014-11-26
CA2733218A1 (en) 2010-01-28
CR20110079A (es) 2011-07-18
BRPI0911699B1 (pt) 2020-11-17
MX2011000768A (es) 2011-10-05
CR20110084A (es) 2011-07-18
WO2010010466A2 (en) 2010-01-28
ES2662519T3 (es) 2018-04-06
RU2553325C2 (ru) 2015-06-10
IL210772A0 (en) 2011-03-31
CN102216327A (zh) 2011-10-12
JP2014237714A (ja) 2014-12-18
NZ590891A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
MX382043B (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201791735A1 (ru) Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
CU23953B1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20150002A1 (es) Anticuerpos anti-fcrn
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20141158A1 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2014013678A (es) Agentes para neutralizacion de influenza.
AR087749A1 (es) Anticuerpos anti-xcr1 humano
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX349235B (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs).
CL2013002836A1 (es) Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena.
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24

Legal Events

Date Code Title Description
FG Grant or registration